NASDAQ:EOCN Galmed Pharmaceuticals Q2 2024 Earnings Results & Report $3.10 -0.12 (-3.73%) As of 10/30/2026 03:57 PM Eastern Galmed Pharmaceuticals reported Q2 2024 earnings on August 28, 2024. The company reported EPS of $17.28. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2024Report DateAugust 28, 2024 Galmed Pharmaceuticals EPS ResultsActual EPS$17.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGalmed Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGalmed Pharmaceuticals' next earnings date is estimated for Wednesday, November 25, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Galmed Pharmaceuticals Q2 2024 Earnings FAQ Did Galmed Pharmaceuticals beat earnings estimates for Q2 2024? Galmed Pharmaceuticals (NASDAQ:EOCN) reported earnings of $17.28 per share for Q2 2024. The report was announced on Wednesday, August 28, 2024. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals' next earnings date is estimated for Wednesday, November 25, 2026. MarketBeat tracks confirmed and estimated earnings dates for Galmed Pharmaceuticals on the company's earnings history page. Galmed Pharmaceuticals Earnings HeadlinesGalmed Pharma Rebrands To EoCene, Debuts EOCN Ticker As GI Expansion Accelerates; Stock UpSeptember 9, 2026 | rttnews.comGalmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI InnovationSeptember 9, 2026 | prnewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 31 at 1:00 AM | Weiss Ratings (Ad)6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & MoreSeptember 3, 2026 | rttnews.comGalmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGMSeptember 3, 2026 | tipranks.comGalmed Pharmaceuticals Ltd.: Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyAugust 19, 2026 | finanznachrichten.deSee More Galmed Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Galmed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galmed Pharmaceuticals and other key companies, straight to your email. Email Address About Galmed PharmaceuticalsGalmed Pharmaceuticals (NASDAQ:EOCN), a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.View Galmed Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's WhyStarbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?Breaching the Valuation: The Real Reason Fortinet Dropped Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
